Metabolic syndrome, dyssomnia, and melatonin DOI Creative Commons

V. O. Serhiyenko,

V.B. Sehin,

Marta Hotsko

et al.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Journal Year: 2024, Volume and Issue: 20(2), P. 133 - 142

Published: April 19, 2024

In recent years, there has been an interest in studying the specifics of relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia insomnia are important risk factors for insulin resistance, obesity, MetS, type 2 diabetes mellitus with a degree influence similar to traditional factors. Thus, treatment dyssomnia is one key tasks prevention MetS. The regulation circadian rhythms by exogenous intervention (in particular, use melatonergic drugs) likely play central role MEL acts as powerful antioxidant that can cross blood-brain barrier, suppress oxidative stress, chronic inflammation, interact gut microbiome. From clinical point view, imbalance may indicate “darkness deficit”. It proven neurohormone systemic effects due its mechanisms action, potential course many diseases. Currently, drugs approved exclusively insomnia, jetlag, depression accompanied disorders. However, potentially therapeutic properties neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune allergic increasing need products prompted search safe but environmentally friendly medicines. reported phytomelatonin have advantages related improved bioavailability efficacy. purpose this review analyze relationship dyssomnia, MEL. was conducted Scopus, Science Direct (from Else­vier), PubMed, including MEDLINE databases. keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive apnea”, “melatonin”. We manual bibliography publications identify research results eluded during online search.

Language: Английский

The relationship between melatonin levels and insulin resistance in patients with type 2 diabetes mellitus under chronic war stress DOI Creative Commons
M.I. Bobryk, Violetta Yuzvenko, Victoria Serhiyenko

et al.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Journal Year: 2025, Volume and Issue: 21(2), P. 185 - 189

Published: April 1, 2025

Background. In recent years, information has emerged about the relationship between melatonin and insulin expression of receptors in central nervous system. The severity deficiency patients with type 2 diabetes mellitus (T2DM) may vary during war. aim study was to assess changes nocturnal levels its resistance T2DM full-scale war Ukraine compared pre-war state. Mate­rials methods. 2021–2024, a prospective conducted, which included aged 19–75 years state compensation (glycated hemoglobin level ≥ 6.5 < 8.0 %). exclusion criteria were: severe chronic complications, glycated %, acute inflammatory processes, oncological diseases, body mass index 40 kg/m2, taking antidepressants, preparations less than months before study. involved 404 from different regions Ukraine. Laboratory assessment saliva performed by solid-phase enzyme-linked immunoassay. Results. frequency increased 54.3 % 2021 70.9 2024. On background an increase number deficiency, there is significant among them individuals elevated HOMA index, 12.5 47.2 Changes distribution results according on indicate rela­tive risk detecting above normal group 6.2 times 2024 (odds ratio 6.2, 95% confidence interval: 1.9–26.5). Conclusions. impact stress insomnia are more factors for pathological deficiency. Patients recommended further correction those since such can lead decrease improvement carbohydrate metabolism.

Language: Английский

Citations

0
Metabolic syndrome, dyssomnia, and melatonin DOI Creative Commons

V. O. Serhiyenko,

V.B. Sehin,

Marta Hotsko

et al.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Journal Year: 2024, Volume and Issue: 20(2), P. 133 - 142

Published: April 19, 2024

In recent years, there has been an interest in studying the specifics of relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia insomnia are important risk factors for insulin resistance, obesity, MetS, type 2 diabetes mellitus with a degree influence similar to traditional factors. Thus, treatment dyssomnia is one key tasks prevention MetS. The regulation circadian rhythms by exogenous intervention (in particular, use melatonergic drugs) likely play central role MEL acts as powerful antioxidant that can cross blood-brain barrier, suppress oxidative stress, chronic inflammation, interact gut microbiome. From clinical point view, imbalance may indicate “darkness deficit”. It proven neurohormone systemic effects due its mechanisms action, potential course many diseases. Currently, drugs approved exclusively insomnia, jetlag, depression accompanied disorders. However, potentially therapeutic properties neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune allergic increasing need products prompted search safe but environmentally friendly medicines. reported phytomelatonin have advantages related improved bioavailability efficacy. purpose this review analyze relationship dyssomnia, MEL. was conducted Scopus, Science Direct (from Else­vier), PubMed, including MEDLINE databases. keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive apnea”, “melatonin”. We manual bibliography publications identify research results eluded during online search.

Language: Английский

Citations

2